PCa Commentary # 146: Radium-223 (Xofigo); A Radioisotope Treatment for Prostate Cancer Metastatic to Bone. The radiobiology of Radium-223 suggests greater effectiveness when used early in metastatic castration-resistant prostate cancer (mCRPC).

In 2013 Radium-223 was FDA approved for treatment of prostate cancer patients with bone metastases on the basis of a large randomized trial, ASYMPCA, comparing the radioisotope to a placebo. In 708 heavily pretreated men, the overall median survival was extended by...